NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $4.66 0.00 (0.00%) As of 10/9/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About CureVac Stock (NASDAQ:CVAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CureVac alerts:Sign Up Key Stats Today's Range$4.66▼$4.6650-Day Range$4.66▼$4.6652-Week Range$3.13▼$5.72VolumeN/AAverage Volume992,546 shsMarket Capitalization$1.05 billionP/E Ratio6.47Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview CureVac N.V. (NASDAQ: CVAC) is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA). Its research programs are aimed at using mRNA to instruct cells to produce therapeutic proteins, with applications in infectious diseases, oncology and other medical conditions. Founded in 2000 and headquartered in Tübingen, Germany, CureVac has developed proprietary mRNA technologies designed to improve the stability, delivery and manufacturing of mRNA-based products. The company has advanced experimental vaccine and therapeutic candidates through preclinical and clinical development, but it does not have a broad portfolio of approved commercial products. CureVac’s programs have included candidates for COVID-19 and seasonal influenza, as well as cancer immunotherapies and other vaccines. The company has conducted research and clinical activities across Europe and the United States and has pursued development and commercialization collaborations, including a strategic partnership with GSK. Alexander Zehnder served as CureVac’s chief executive officer beginning in 2023.AI Generated. May Contain Errors. Read More CureVac Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreCVAC MarketRank™: CureVac scored higher than 1% of companies evaluated by MarketBeat, and ranked 881st out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingCureVac has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCureVac has received no research coverage in the past 90 days.Read more about CureVac's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is 6.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is 6.47, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.01.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CVAC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for CureVac this week, compared to 0 articles on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by Insiders2.15% of the stock of CureVac is held by insiders.Percentage Held by Institutions17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVAC Stock News HeadlinesReviewing CollPlant Biotechnologies (NASDAQ:CLGN) & CureVac (NASDAQ:CVAC)October 6, 2026 | americanbankingnews.comReviewing CureVac (NASDAQ:CVAC) & Longeveron (NASDAQ:LGVN)October 2, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 11 at 1:00 AM | Chaikin Analytics (Ad)CureVac sues Moderna for patent infringement over COVID-19 vaccinesApril 24, 2026 | reuters.comCureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation PlanJanuary 22, 2026 | finance.yahoo.comBioNTech Completes CureVac Takeover and Updates Articles of AssociationJanuary 6, 2026 | tipranks.comBioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.December 23, 2025 | insidermonkey.comBioNTech Completes CureVac Acquisition to Bolster mRNA LeadershipDecember 18, 2025 | tipranks.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $4.52 at the beginning of the year. Since then, CVAC stock has increased by 3.1% and is now trading at $4.66. How were CureVac's earnings last quarter? CureVac N.V. (NASDAQ:CVAC) released its quarterly earnings data on Monday, November, 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.07. The business had revenue of $63.53 million for the quarter, compared to the consensus estimate of $21.40 million. CureVac had a net margin of 199.92% and a negative trailing twelve-month return on equity of 23.03%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,333,333 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers. How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings11/24/2025Today10/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CVAC's financial health is in the Green zone, according to TradeSmith. CVAC has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CVAC CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees880Year Founded2000Profitability EPS (Trailing Twelve Months)$0.72 Trailing P/E Ratio6.47 Forward P/E Ratio6.47 P/E GrowthN/ANet Income$175.50 million Net Margins199.92% Pretax Margin232.79% Return on Equity-23.03% Return on Assets-19.09% Debt Debt-to-Equity Ratio0.03 Current Ratio3.70 Quick Ratio3.69 Sales & Book Value Annual Sales$70.74 million Price / Sales14.78 Cash Flow$0.99 per share Price / Cash Flow4.73 Book Value$3.36 per share Price / Book1.39Miscellaneous Outstanding Shares224,338,000Free Float219,515,000Market Cap$1.05 billion OptionableNo Data Beta1.77 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CVAC) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVAC Stock Alerts